News Feature

The complement pathway’s intricate network of proteins, which have a key role in the innate immune system, are attracting dealmakers’ attention as targets for a variety of inflammatory diseases.

2019 has seen a boom in high-value M&A and licensing deals, with oncology and rare diseases as prominent themes.

Even for the most seasoned dealmakers, successful deals require coordination, planning and collaboration throughout the process. This article explores the people and stages required to close a successful licensing and collaboration deal from the perspective of dealmakers at Eli Lilly.

Antiviral and vaccine R&D for the common, deadly, and elusive influenza virus is increasingly focused on targets less likely to evade treatments.

Immuno-oncology continues to be a highly active area for dealmaking as leading companies seek to expand the treatable patient population for checkpoint inhibitors in indications such as non-small-cell lung cancer and achieve initial success in indications such as pancreatic cancer.

As a key component in deal negotiations, a term sheet must be planned carefully and set out optimally for an asset. Lubor Gaal from Locust Walk discusses how licencors can negotiate the best terms for their biopharma assets.

July and August saw a handful of high-value deals during what is usually a quiet time for dealmaking. In the most valuable deal in this period and also one of the largest this year, Amgen paid Celgene $13.4 billion for Otezla, an oral psoriasis therapy.

Established monoclonal antibody therapies have had unprecedented levels of commercial success, but the market is now changing owing to patent expirations and the rise of cancer immunotherapies

Opportunities are rising for small biotech companies but so are challenges in scaling. In the first of our Thought Leader series, Marc Funk, CEO of Lonza, talks to us about the new business models and technology the company is developing to help companies remain independent.

Plentiful acquisitions, increased financing and pioneering digital health approvals all shaped the medtech industry in 2018. With nontraditional players such as Apple and Google engaging in the field, the industry looks set to evolve further.

Over the past year, the biopharma industry has witnessed some landmark approvals, high-value merger and acquisition deals and phenomenal venture funding in the US. In this feature, we chart the key trends in biopharma dealmaking since June 2018.

At one of its most exciting phases of growth, the cell and gene therapy market has gained momentum in dealmaking, product sales and big pharma interest, all of which are analyzed in this feature.

In the largest deal of the month and the second largest M&A of the year, AbbVie announced its $63 billion acquisition of Allergan.

The validation of novel therapeutic modalities such as gene therapy is supporting deal activity and investment in the development of drugs for central nervous system disorders, particularly for neurodegenerative diseases.

A handful of notable acquisitions took place in May, bringing in assets and platforms for major biopharma companies.

Development and regulatory milestone payments are a key element of many biopharma deals. This article analyses some of the trends involving these payments over the last decade.

We bring together recent therapy and technology features, based upon some of March's largest biopharma deals.

Oncology remains the most active area for dealmaking; in 2018, projected deal values increased substantially, driven by deals in immuno-oncology, and a number of major mergers and acquisitions were announced. In this feature, authors at Clarivate Analytics explore the trends in recent oncology deals.

We bring together recent therapy and technology features, based upon some of February's largest biopharma deals.

We bring together recent therapy and technology features, based upon some of January's largest biopharma deals.